MASI — Melasma Area and Severity Index
Standard quantitative melasma severity score (Kimbrough-Green 1994, modified Pandya 2011). Total 0–48 (0–24 for mMASI). Used in clinical trials and PROM monitoring.
Score interpretation
→ Daily broad-spectrum SPF 50+ (mineral preferred); avoid heat / friction; topical Kligman trio (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%) 8 weeks; tranexamic acid 250 mg BD (off-label).
→ Continue topical regime; consider chemical peels (glycolic acid, mandelic acid); oral tranexamic acid 250–500 mg BD for 3 months.
→ Specialist dermatology input. Q-switched / fractionated lasers (use cautiously — risk of post-inflammatory hyperpigmentation). Combination peels + lasers. Long-term photoprotection critical to prevent recurrence.
Interpretation bands for the MASI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Risperidone (Paediatric) · Atypical Antipsychotic — Autism Spectrum Disorder / Schizophrenia / Tic Disorders
- Carbamazepine (Paediatric) · Antiepileptic — Focal Seizures / Trigeminal Neuralgia / Bipolar Disorder
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Lisdexamfetamine · CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)
- Alglucosidase Alfa · Enzyme Replacement Therapy (Lysosomal Storage Disorder)
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.